This inhibitor showed in vivo efficacy against models of lung cancer expressing Exon19Del-, L858R-, and C797S-EGFR [106,107], but the phase I/II clinical trial (HARMONY) was terminated due to a lack of efficacy. This evidence concerns the gene EGFR and lung cancer.